Treatment of Alzheimer's disease: Rationale and strategies

Neurologic Clinics

Volumn 18, Issue 4, 2000, Pages 807-827

  Grundman, Michael ^b   Thal, Leon J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; ALPHA TOCOPHEROL; ALVAMELINE; AMYLOID PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; GINKGO BILOBA EXTRACT; HEPTYLSTIGMINE TARTRATE; HORMONE; IDEBENONE; LETEPRINIM; METRIFONATE; MUSCARINIC AGENT; NEUROTROPHIC FACTOR; NICOTINIC AGENT; PHYSOSTIGMINE; RIVASTIGMINE; ROFECOXIB; SABCOMELINE; SABELUZOLE; SYNAPTON; TACRINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANOREXIA; APLASTIC ANEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHINITIS;

EID: 0034518231     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70227-9     Document Type: Article

References (165)

1. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy
2. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study
3. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
4. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?
5. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21
6. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease
7. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties
8. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study
9. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices
10. The influence of estrous cycle and intrastriatal estradiol on sensorimotor performance in the female rat
11. Potential pharmacotherapy of Alzheimer disease: A comparison of various forms of physostigmine administration
12. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
13. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine
14. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies
15. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
16. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
17. Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons
18. The effects of donepezil in Alzheimer's disease: Results from a multinational trial
19. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada
20. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
21. Metrifonate treatment of the cognitive deficits of Alzheimer's disease: Metrifonate Study Group
22. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
23. Cholinergic strategies in the treatment of Alzheimer's disease
24. Selective loss of central cholinergic neurons in Alzheimer's disease
25. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine
26. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease: The Tacrine Collaborative Study Group
27. Cholinergic therapies for Alzheimer's disease: Palliative or disease altering?
28. Estrogen improves psychological function in asymptomatic postmenopausal women
29. Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues
30. Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds
31. Complement activation in amyloid plaques in Alzheimer's dementia
32. Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
33. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease
34. Clinical effects of choline in Alzheimer's disease
35. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease
36. A controlled trial of tacrine in Alzheimer's disease: The Tacrine Study Group
37. Disease stage severity at baseline influenced progression rate in a 48-week selegiline Alzheimer's disease treatment trial
38. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type
39. The cholinergic hypothesis of Alzheimer's disease: A review of progress
40. L-Deprenyl in Alzheimer's disease: Cognitive and behavioral effects
41. Morphological response of axotomized septal neurons to nerve growth factor
42. Cognitive impairment and mortality in a cohort of elderly people
43. Cholinesterase inhibitors: From preclinical studies to clinical efficacy in Alzheimer disease
44. Cholinesterase inhibitors: From the calabar bean to Alzheimer therapy
45. Present progress and future development in the therapy for Alzheimer's disease
46. Ginkgo biloba
47. Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture
48. Effect of AIT-082, a purine analog, on working memory in normal and aged mice
49. Association between nutritional status and cognitive functioning in a healthy elderly population
50. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood
51. Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience
52. Vitamin E and Alzheimer's disease: The basis for additional clinical trials
53. Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy
54. Importance of both clinical and marital status on survival in Alzheimer's disease
55. A phase I study of AIT-082 in healthy elderly volunteers
56. Demonstration of microglial cells In and around senile (neuritic) plaques in the Alzheimer brain: An immunohistochemical study using a novel monoclonal antibody
57. Preclinical and clinical progress with Huperzine A: A novel acetylcholinesterase inhibitor
58. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects
59. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
60. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease
61. Idebenone protects against oxidative stress mediated neuronal cell death by coupling with the mitochondrial electron transport system
62. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
63. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type)
64. Estrogen as a growth factor to central nervous cells: Estrogen treatment promotes development of acetylcholinesterase-positive basal forebrain neurons transplanted in the anterior eye chamber
65. Identification of a novel aspartic protease (Asp 2) as beta-secretase
66. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease
67. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
68. Two-year treatment of Alzheimer's disease with eptastigmine
69. Complements, microglial cells and amyloid fibril formation
70. Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles
71. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease
72. The prevalence of dementia: A quantitative integration of the literature
73. Reduction of motor behavioural deficits in senescence via chronic prolactin or estrogen administration: Time course and putative mechanisms of action
74. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
75. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
76. Nutritional status and cognitive functioning in a normally aging sample: A 6-y reassessment
77. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia: North American EGb Study Group
78. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies
79. Nicotinic acetylcholine involvement in cognitive function in animals
80. Inhibition of amyloid-beta fibrillogenesis
81. Novel nicotinic compounds for Aizheimer's disease therapy
82. Estradiol increases choline acetyltransferase activity in specific basal fore-brain nuclei and projection areas of female rats
83. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments
84. Association of Gingko biloba with intracerebral hemorrhage
85. Hormone replacement therapy and other potential treatments for dementias
86. Effects of estrogen treatment on sensorimotor task performance and brain dopamine concentrations in gonadectomized male and female CD-1 mice
87. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain
88. Activation of the classical complement pathway in brain tissue of Alzheimer patients
89. Immune system response in Alzheimer's disease
90. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease
91. AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC 12 cells
92. Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year prospective placebo-controlled study
93. Reappraising neurotransmitter-based strategies
94. The Clinical Dementia Rating (CDR): Current version and scoring rules
95. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
96. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease
97. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial: Alzheimer's Disease Cooperative Study
98. Nicotinic system involvement in Alzheimer's and Parkinson's diseases: Implications for therapeutics
99. Intravenous nicotine in Alzheimer's disease: A pilot study
100. Neuroreceptor changes in Alzheimer disease
101. Complement and beta-amyloid neurotoxicity in vitro: A model for Alzheimer's disease
102. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type
103. Does Alzheimer's disease start early in life?
104. Estrogen deficiency and risk of Alzheimer's disease in women
105. Estrogen replacement therapy and risk of Alzheimer disease
106. Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: A pilot double blind transdermal nicotine positron emission tomography study
107. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain
108. Neuroactive steroids
109. The relation between antioxidants and memory performance in the old and very old
110. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
111. Effects of physostigmine and lecithin on memory in Alzheimer disease
112. Mild cognitive impairment: Clinical characterization and outcome
113. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
114. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells
115. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
116. Clinical trial of indomethacin in Alzheimer's disease
117. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study: Donepezil Study Group
118. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group
119. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
120. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
121. A new rating scale for Alzheimer's disease
122. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract
123. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
124. Aricept-induced nightmares in Alzheimer's disease: 2 Case reports
125. Nicotinic stimulation of [3H]acetylcholine release from mouse cerebral cortical synaptosomes
126. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion
127. Estradiol in the striatum: Effects on behavior and dopamine receptors but no evidence for membrane steroid receptors
128. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease
129. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative Study
130. Moving from treatment to prevention in Alzheimer's disease with vitamin E and estrogen
131. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
132. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
133. Metrifonate: A cholinesterase inhibitor for Alzheimer's disease therapy
134. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease
135. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands
136. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women
137. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease
138. Purification and cloning of amyloid precursor protein beta-secretase from human brain
139. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy
140. Alzheimer's disease: Antibody clears senile plaques
141. Risk of Alzheimer's disease and duration of NSAID use
142. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
143. Use of THA in treatment of Alzheimer like dementia: Pilot study in twelve patients
144. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease
145. A 5-month, randomized, placebo-controlled trial of galantamine in AD
146. Cholinomimetic treatment of Alzheimer's disease
147. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease
148. Oral physostigmine and lecithin improve memory in Alzheimer disease
149. Choline chloride fails to improve cognition of Alzheimer's disease
150. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain
151. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain?
152. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
153. Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients
154. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl] thio]phenol hydrochloride (SIB-1553A): A novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors
155. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease
156. The association of weight change in Alzheimer's disease with severity of disease and mortality: A longitudinal analysis
157. Nicotinic acetylcholine binding sites in Alzheimer's disease
158. Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions
159. Galanthamine hydrobromide: Interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type
160. Donepezil enhances global function, cognition, and activities of daily living compared to placebo in a one year, double-blind trial in patients with mild to moderate Alzheimer's disease
161. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease
162. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity